About this item:

18 Views | 29 Downloads

Author Notes:

Correspondence: Stanley M. Fineman

Disclosures: Dr Fineman reports serving as a clinical investigator for Aimmune Therapeutics, Biocryst Pharmaceuticlas, Inc, DBV Technologies, and Regeneron; and as a speaker/teacher for Takeda Pharmaceutical Company Limited.

Dr Mahr reports serving as a speaker/teacher for AstraZeneca, GlaxoSmithKline, Kaleo, Inc, Optinose US, Inc, Regeneron, and Sanofi; and served as a consultant of Kaleo, Inc, Regeneron, and Sanofi.

Dr Chipps served on the advisory board and as a consultant or a speaker/teacher for Circassia, Genentech, Inc, Novartis, Regeneron, Sanofi, and Teva Pharmaceutical Industries Ltd. Dr Lee has no conflicts of interest to report.


Research Funding:

The authors have no funding sources to report.


  • Science & Technology
  • Life Sciences & Biomedicine
  • Allergy
  • Immunology

From the pages of AllergyWatch (R)


Journal Title:

Annals of Allergy, Asthma & Immunology


Volume 126, Number 4


, Pages 444-445

Type of Work:

Article | Final Publisher PDF


For this issue of “From the Pages of AllergyWatch,” I have selected 2 articles related to coronavirus disease 2019 (COVID-19) and asthma. The first review by Dr Lee from the November-December AllergyWatch postulates that the angiotensin-converting enzyme 2 (ACE2) receptors may be protective in our patients with allergic asthma and reduce the risk for hospitalization with COVID-19. The next article, reviewed by Dr Mahr from the September-October AllergyWatch, warns about stepping down controllers in pediatric patients with asthma during the pandemic. The last article, reviewed by Dr Chipps, evaluated the role of exhaled nitric oxide (eNO) as a guide to inhaled corticosteroid (ICS) stepdown decisions for our patients with asthma

Copyright information:

© 2021 Published by Elsevier Inc. on behalf of American College of Allergy, Asthma & Immunology.

This is an Open Access work distributed under the terms of the Creative Commons Attribution 4.0 International License (https://creativecommons.org/licenses/by/4.0/rdf).
Export to EndNote